Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022
28 juil. 2022 07h30 HE
|
Passage Bio
PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 juil. 2022 16h01 HE
|
Passage Bio
PHILADELPHIA, July 21, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors
06 juil. 2022 07h00 HE
|
Passage Bio
PHILADELPHIA, July 06, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
09 juin 2022 07h30 HE
|
Passage Bio
PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy
08 juin 2022 07h30 HE
|
Passage Bio
• PBML04 represents the company’s fourth program to receive IND clearance PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines...
Passage Bio Announces Leadership Transition
01 juin 2022 07h30 HE
|
Passage Bio
Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition periodEdgar B. (Chip) Cale, current...
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
20 mai 2022 16h01 HE
|
Passage Bio
PHILADELPHIA, May 20, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting
18 mai 2022 07h00 HE
|
Passage Bio
Longer-term follow-up showed continued developmental improvement for both patients in assessments by study investigators and caregiversInterim safety data at 13 and seven months from patients in...
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
16 mai 2022 07h00 HE
|
Passage Bio
Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22Dosed first...
Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022
09 mai 2022 07h00 HE
|
Passage Bio
PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...